

**Clinical trial results:****A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects with Moderate to Severe Hidradenitis Suppurativa - PIONEER I Summary**

EudraCT number	2011-003400-20
Trial protocol	DE CZ HU
Global end of trial date	16 March 2014

Results information

Result version number	v1 (current)
This version publication date	20 April 2016
First version publication date	01 August 2015

Trial information**Trial identification**

Sponsor protocol code	M11-313
-----------------------	---------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01468207
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	AbbVie
Sponsor organisation address	1 North Waukegan Road, North Chicago, IL, United States, 60064
Public contact	Global Medical Information, AbbVie, 001 800-633-9110,
Scientific contact	David Williams MD, AbbVie, david.a.williams@abbvie.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	Yes
EMA paediatric investigation plan number(s)	EMA-000366-PIP04-12
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	16 March 2014
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	16 March 2014
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To evaluate the safety and efficacy of treatment with adalimumab in adults with moderate to severe hidradenitis suppurativa (HS).

Protection of trial subjects:

Subject and/or legal guardian read and understood the information provided about the study and gave written permission.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	29 November 2011
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 19
Country: Number of subjects enrolled	Canada: 34
Country: Number of subjects enrolled	United States: 155
Country: Number of subjects enrolled	Czech Republic: 31
Country: Number of subjects enrolled	Germany: 55
Country: Number of subjects enrolled	Hungary: 13
Worldwide total number of subjects	307
EEA total number of subjects	99

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0

Adults (18-64 years)	304
From 65 to 84 years	3
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Subjects were enrolled at 48 investigative sites in Australia, Canada, Czech Republic, Germany, Hungary, and the United States.

Pre-assignment

Screening details:

Subjects ≥ 18 years of age with hidradenitis suppurativa (HS) for at least 1 year prior to Baseline and HS lesions present in at least 2 distinct anatomical areas (one of which must be at least Hurley Stage II or III) who had experienced inadequate response to ≥ 90 day treatment of oral antibiotics for HS were eligible for enrolment in the study.

Period 1

Period 1 title	Treatment Period 1
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Carer, Assessor

Arms

Are arms mutually exclusive?	Yes
Arm title	Placebo

Arm description:

Placebo for 12 weeks.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Placebo pre-filled syringe, administered by subcutaneous injection

Arm title	Adalimumab Every Week (EW)
------------------	----------------------------

Arm description:

Adalimumab ew for 12 weeks (160 mg at Week 0; 80 mg at Week 2; and 40 mg ew from Week 4 to Week 12).

Arm type	Experimental
Investigational medicinal product name	Adalimumab
Investigational medicinal product code	
Other name	Humira
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Adalimumab pre-filled syringe, administered by subcutaneous injection

Number of subjects in period 1	Placebo	Adalimumab Every Week (EW)
Started	154	153
Received study drug	152	153
Completed	145	145
Not completed	9	8
Consent withdrawn by subject	5	4
Other, not specified	-	2
Adverse event	1	-
Lost to follow-up	2	1
Protocol deviation	1	1

Period 2

Period 2 title	Treatment Period 2
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Carer, Assessor

Arms

Are arms mutually exclusive?	Yes
Arm title	Placebo/Adalimumab Every Week (EW)

Arm description:

Subjects randomized to receive placebo in Period 1 received adalimumab 160 mg at Week 12, 80 mg at Week 14, and 40 mg ew from Week 16 to Week 35 in Period 2 (up to 24 weeks).

Arm type	Experimental
Investigational medicinal product name	Adalimumab
Investigational medicinal product code	
Other name	Humira
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Adalimumab pre-filled syringe, administered by subcutaneous injection

Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Placebo pre-filled syringe, administered by subcutaneous injection

Arm title	Adalimumab Every Week (EW)/Placebo
------------------	------------------------------------

Arm description:

Subjects randomized to receive adalimumab ew in Period 1 were re-randomized to receive placebo ew from Week 12 to Week 35 in Period 2 (up to 24 weeks).

Arm type	Placebo
----------	---------

Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Placebo pre-filled syringe, administered by subcutaneous injection

Investigational medicinal product name	Adalimumab
Investigational medicinal product code	
Other name	Humira
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Adalimumab pre-filled syringe, administered by subcutaneous injection

Arm title	Adalimumab Every Week (EW)/ Adalimumab Every Other Week (EOW)
------------------	---

Arm description:

Subjects randomized to receive adalimumab ew in Period 1 were re-randomized to receive adalimumab 40 mg eow from Week 12 to Week 35 in Period 2; placebo injections were administered eow from Week 13 to Week 35 (up to 24 weeks).

Arm type	Experimental
Investigational medicinal product name	Adalimumab
Investigational medicinal product code	
Other name	Humira
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Adalimumab pre-filled syringe, administered by subcutaneous injection

Arm title	Adalimumab Every Week (EW)/Adalimumab Every Week (EW)
------------------	---

Arm description:

Subjects randomized to receive adalimumab ew in Period 1 were re-randomized to receive 40 mg adalimumab ew from Week 12 to Week 35 in Period 2 (up to 24 weeks).

Arm type	Experimental
Investigational medicinal product name	Adalimumab
Investigational medicinal product code	
Other name	Humira
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Adalimumab pre-filled syringe, administered by subcutaneous injection

Number of subjects in period 2	Placebo/Adalimumab Every Week (EW)	Adalimumab Every Week (EW)/Placebo	Adalimumab Every Week (EW)/ Adalimumab Every Other Week (EOW)
	Started	145	49
Completed	93	22	27
Not completed	52	27	21
Consent withdrawn by subject	5	-	-
Other, not specified	5	1	1

Adverse event	6	1	2
Loss or absence of response (per protocol)	30	23	18
Lost to follow-up	5	1	-
Lack of efficacy	1	1	-

Number of subjects in period 2	Adalimumab Every Week (EW)/Adalimumab Every Week (EW)
Started	48
Completed	28
Not completed	20
Consent withdrawn by subject	2
Other, not specified	2
Adverse event	1
Loss or absence of response (per protocol)	13
Lost to follow-up	-
Lack of efficacy	2

Baseline characteristics

Reporting groups

Reporting group title	Placebo
Reporting group description: Placebo for 12 weeks.	
Reporting group title	Adalimumab Every Week (EW)
Reporting group description: Adalimumab ew for 12 weeks (160 mg at Week 0; 80 mg at Week 2; and 40 mg ew from Week 4 to Week 12).	

Reporting group values	Placebo	Adalimumab Every Week (EW)	Total
Number of subjects	154	153	307
Age categorical Units: Subjects			

Age continuous Units: years arithmetic mean standard deviation	37.8 ± 11.33	36.2 ± 10.83	-
Gender categorical Units: Subjects			
Female	105	91	196
Male	49	62	111

End points

End points reporting groups

Reporting group title	Placebo
Reporting group description:	Placebo for 12 weeks.
Reporting group title	Adalimumab Every Week (EW)
Reporting group description:	Adalimumab ew for 12 weeks (160 mg at Week 0; 80 mg at Week 2; and 40 mg ew from Week 4 to Week 12).
Reporting group title	Placebo/Adalimumab Every Week (EW)
Reporting group description:	Subjects randomized to receive placebo in Period 1 received adalimumab 160 mg at Week 12, 80 mg at Week 14, and 40 mg ew from Week 16 to Week 35 in Period 2 (up to 24 weeks).
Reporting group title	Adalimumab Every Week (EW)/Placebo
Reporting group description:	Subjects randomized to receive adalimumab ew in Period 1 were re-randomized to receive placebo ew from Week 12 to Week 35 in Period 2 (up to 24 weeks).
Reporting group title	Adalimumab Every Week (EW)/ Adalimumab Every Other Week (EOW)
Reporting group description:	Subjects randomized to receive adalimumab ew in Period 1 were re-randomized to receive adalimumab 40 mg eow from Week 12 to Week 35 in Period 2; placebo injections were administered eow from Week 13 to Week 35 (up to 24 weeks).
Reporting group title	Adalimumab Every Week (EW)/Adalimumab Every Week (EW)
Reporting group description:	Subjects randomized to receive adalimumab ew in Period 1 were re-randomized to receive 40 mg adalimumab ew from Week 12 to Week 35 in Period 2 (up to 24 weeks).
Subject analysis set title	Placebo - Baseline Hurley Stage II
Subject analysis set type	Intention-to-treat
Subject analysis set description:	Subjects with baseline Hurley Stage II randomized to receive placebo every week (ew) for 12 weeks.
Subject analysis set title	Placebo - Baseline Hurley Stage III
Subject analysis set type	Intention-to-treat
Subject analysis set description:	Subjects with baseline Hurley Stage III randomized to receive placebo every week (ew) for 12 weeks.
Subject analysis set title	Adalimumab Every Week (EW) - Baseline Hurley Stage II
Subject analysis set type	Intention-to-treat
Subject analysis set description:	Subjects with baseline Hurley Stage II randomized to receive adalimumab ew 160 mg at Week 12, 80 mg at Week 14, and 40 mg ew from Week 16 to 35 (up to 24 weeks).
Subject analysis set title	Adalimumab Every Week (ew) - Baseline Hurley Stage III
Subject analysis set type	Intention-to-treat
Subject analysis set description:	Subjects with baseline Hurley Stage III randomized to receive adalimumab ew 160 mg at Week 12, 80 mg at Week 14, and 40 mg ew from Week 16 to 35 (up to 24 weeks).
Subject analysis set title	Placebo - Baseline NRS at Worst ≥ 3
Subject analysis set type	Intention-to-treat
Subject analysis set description:	Subjects with baseline Patient's Global Assessment of Skin Pain Numeric Rating Scale (NRS) ≥ 3 randomized to receive placebo every week (ew) for 12 weeks.
Subject analysis set title	Adalimumab Every Week (EW) - Baseline NRS at Worst ≥ 3
Subject analysis set type	Intention-to-treat

Subject analysis set description:

Subjects with baseline Patient's Global Assessment of Skin Pain Numeric Rating Scale (NRS) ≥ 3 randomized to receive adalimumab ew 160 mg at Week 12, 80 mg at Week 14, and 40 mg ew from Week 16 to 35 (up to 24 weeks).

Primary: Percentage of Subjects Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12

End point title	Percentage of Subjects Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12
-----------------	--

End point description:

Hidradenitis Suppurativa Clinical Response (HiSCR) was defined as at least a 50% reduction in abscess and inflammatory nodule (AN) count with no increase in abscess count and no increase in draining fistula count at Week 12 relative to Baseline. Data are presented for all subjects and by baseline Hurley Stage (Stage 1: Abscess formation, single or multiple, without sinus tracts and scarring; Stage II: One or more widely separated recurrent abscesses with tract formation and scars. A subject with at least 1 anatomic region with Hurley Stage II disease and with no anatomic regions with Hurley Stage III disease was classified as Hurley Stage II; and Stage III: Multiple interconnected tracts and abscesses across the entire area, with diffuse or near diffuse involvement. A subject with at least 1 anatomic region with Hurley Stage III disease was classified as Hurley Stage III). Non-responder imputation (NRI): Subjects with missing data were considered non-responders.

End point type	Primary
----------------	---------

End point timeframe:

Baseline (Week 0) up to Week 12

End point values	Placebo	Adalimumab Every Week (EW)	Placebo - Baseline Hurley Stage II	Placebo - Baseline Hurley Stage III
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	154	153	84	70
Units: percentage of subjects				
number (not applicable)	26	41.8	29.8	21.4

End point values	Adalimumab Every Week (EW) - Baseline Hurley Stage II	Adalimumab Every Week (ew) - Baseline Hurley Stage III		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	83	70		
Units: percentage of subjects				
number (not applicable)	44.6	38.6		

Statistical analyses

Statistical analysis title	Statistical Analysis 1
----------------------------	------------------------

Statistical analysis description:

The p-value was calculated from the Cochran-Mantel-Haenszel test adjusted for baseline Hurley Stage.

Comparison groups	Placebo v Adalimumab Every Week (EW)
-------------------	--------------------------------------

Number of subjects included in analysis	307
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.003
Method	Cochran-Mantel-Haenszel
Parameter estimate	Adjusted mean difference
Point estimate	15.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	5.3
upper limit	26.5

Statistical analysis title	Statistical Analysis 2
-----------------------------------	------------------------

Statistical analysis description:

The p-value was calculated based on chi-square test.

Comparison groups	Placebo - Baseline Hurley Stage II v Adalimumab Every Week (EW) - Baseline Hurley Stage II
Number of subjects included in analysis	167
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.048
Method	Chi-squared
Parameter estimate	Mean difference (final values)
Point estimate	14.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.3
upper limit	29.3

Statistical analysis title	Statistical Analysis 3
-----------------------------------	------------------------

Statistical analysis description:

The p-value was calculated based on chi-square test.

Comparison groups	Adalimumab Every Week (ew) - Baseline Hurley Stage III v Placebo - Baseline Hurley Stage III
Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.027
Method	Chi-squared
Parameter estimate	Mean difference (final values)
Point estimate	17.1

Confidence interval	
level	95 %
sides	2-sided
lower limit	2.2
upper limit	32.1

Secondary: Percentage of Subjects with Baseline Hurley Stage II who Achieved Abscess and Inflammatory Nodule (AN) Count of 0, 1, or 2 at Week 12

End point title	Percentage of Subjects with Baseline Hurley Stage II who Achieved Abscess and Inflammatory Nodule (AN) Count of 0, 1, or 2 at Week 12
End point description:	The percentage of subjects with AN counts lowered to 0, 1, or 2 at Week 12 among subjects with Hurley Stage II at Baseline. Non-responder imputation (NRI): Subjects with missing data were considered non-responders.
End point type	Secondary
End point timeframe:	Baseline (Week 0) up to Week 12

End point values	Placebo - Baseline Hurley Stage II	Adalimumab Every Week (EW) - Baseline Hurley Stage II		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	84	83		
Units: percentage of subjects				
number (not applicable)	28.6	28.9		

Statistical analyses

Statistical analysis title	Statistical analysis 1
Statistical analysis description:	Secondary end points 1 (AN 0/1/2 counts), 2 (NRS30), and 3 (modified Sartorius score) were ranked analyses. The p-value for the AN 0/1/2 counts end point was calculated from the Chi Squared test.
Comparison groups	Placebo - Baseline Hurley Stage II v Adalimumab Every Week (EW) - Baseline Hurley Stage II
Number of subjects included in analysis	167
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.961
Method	Chi-squared
Parameter estimate	Mean difference (final values)
Point estimate	0.3

Confidence interval	
level	95 %
sides	2-sided
lower limit	-13.4
upper limit	14.1

Secondary: Percentage of Subjects Achieving At Least 30% Reduction and At Least 1 Unit Reduction from Baseline in Patient's Global Assessment of Skin Pain (NRS30) – At Worst at Week 12 Among Subjects with Baseline Skin Pain NRS \geq 3

End point title	Percentage of Subjects Achieving At Least 30% Reduction and At Least 1 Unit Reduction from Baseline in Patient's Global Assessment of Skin Pain (NRS30) – At Worst at Week 12 Among Subjects with Baseline Skin Pain NRS \geq 3
-----------------	---

End point description:

The Patient's Global Assessment of Skin Pain Numeric Rating Scale (NRS) was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The assessments were completed on a daily diary by subjects before they went to bed and responded to the items based on a recall period of the "last 24 hours." The percentage of subjects who achieved at least 30% reduction and at least 1 unit reduction from Baseline in the Patient's Global Assessment of Skin Pain (NRS30) – at worst at Week 12 among subjects with Baseline NRS \geq 3 is presented. Weekly averages of daily assessments were analyzed. Non-responder imputation (NRI): Subjects with missing data were considered non-responders.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Week 0) up to Week 12

End point values	Placebo - Baseline NRS at Worst \geq 3	Adalimumab Every Week (EW) - Baseline NRS at Worst \geq 3		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	109	122		
Units: percentage of subjects				
number (not applicable)	24.8	27.9		

Statistical analyses

Statistical analysis title	Statistical analysis 1
-----------------------------------	------------------------

Statistical analysis description:

Secondary end points 1 (AN 0/1/2 counts), 2 (NRS30), and 3 (modified Sartorius score) were ranked analyses. The p-value for the NRS30 end point was calculated from the Cochran-Mantel-Haenszel test adjusted for baseline Hurley Stage.

Comparison groups	Placebo - Baseline NRS at Worst \geq 3 v Adalimumab Every Week (EW) - Baseline NRS at Worst \geq 3
-------------------	--

Number of subjects included in analysis	231
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.628
Method	Cochran-Mantel-Haenszel
Parameter estimate	Adjusted mean difference
Point estimate	2.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-8.6
upper limit	14.2

Secondary: Change from Baseline to Week 12 in Modified Sartorius Score

End point title	Change from Baseline to Week 12 in Modified Sartorius Score
End point description:	
<p>The Sartorius Scale is used to quantify the severity of HS. Points are awarded for 12 body areas (left and right axillae, left and right sub/inframammary areas, intermammary area, left and right buttocks, left and right inguino-crural folds, perianal area, perineal area, and other): points were awarded for nodules (2 points for each); abscesses (4 points); fistulas (4 points); scars (1 point); other findings (1 point); and longest distance between two lesions (2-6 points, 0 if no lesions); and if lesions are separated by normal skin (yes-0 points; No-6 points). The total Sartorius score is the sum of the 12 regional scores. Last Observation Carried Forward (LOCF): The last completed evaluation from the previous visit within the particular period for efficacy measures was carried forward to impute missing data at later visits in the same period. Baseline efficacy evaluations were not carried forward.</p>	
End point type	Secondary
End point timeframe:	
Baseline (Week 0) and Week 12	

End point values	Placebo	Adalimumab Every Week (EW)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	151	153		
Units: units on a scale				
least squares mean (standard error)	-15.7 (± 4)	-24.4 (± 3.97)		

Statistical analyses

Statistical analysis title	Statistical analysis 1
Statistical analysis description:	
<p>Secondary end points 1 (AN 0/1/2 counts), 2 (NRS30), and 3 (modified Sartorius score) were ranked analyses. The p-value for the modified Sartorius score end point was calculated from ANCOVA with stratum, baseline, and treatment as covariates.</p>	
Comparison groups	Placebo v Adalimumab Every Week (EW)

Number of subjects included in analysis	304
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.124
Method	ANCOVA
Parameter estimate	LS mean difference
Point estimate	-8.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-19.7
upper limit	2.4

Adverse events

Adverse events information

Timeframe for reporting adverse events:

AEs were collected from first dose of study drug until 70 days following last dose of study drug (46 weeks); SAEs were collected from the time that informed consent was obtained (up to 50 weeks).

Adverse event reporting additional description:

AEs with onset in Period 1 were collected from first dose of study drug until prior to the first dose in Period 2, or up to 70 days following last dose of study drug if the subject discontinued during Period 1.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	16.1
--------------------	------

Reporting groups

Reporting group title	Placebo (Period 1)
-----------------------	--------------------

Reporting group description:

Placebo for 12 weeks

Reporting group title	Adalimumab EW (Period 1)
-----------------------	--------------------------

Reporting group description:

Adalimumab every week (ew) for 12 weeks (160 mg at Week 0; 80 mg at Week 2; and 40 mg ew from Week 4 to Week 12).

Reporting group title	Placebo/Adalimumab EW (Period 2)
-----------------------	----------------------------------

Reporting group description:

Subjects randomized to receive placebo in Period 1 were re-randomized to receive adalimumab 160 mg at Week 12, 80 mg at Week 14, and 40 mg every week (ew) from Week 16 to Week 35 in Period 2 (up to 24 weeks).

Reporting group title	Adalimumab EW/Placebo (Period 2)
-----------------------	----------------------------------

Reporting group description:

Subjects randomized to receive adalimumab every week (ew) in Period 1 were re-randomized to receive placebo ew from Week 12 to Week 35 in Period 2 (up to 24 weeks).

Reporting group title	Adalimumab EW/ Adalimumab EOW (Period 2)
-----------------------	--

Reporting group description:

Subjects randomized to receive adalimumab every week (ew) in Period 1 were re-randomized to receive adalimumab 40 mg every other week (eow) from Week 12 to Week 35 in Period 2; placebo injections were administered eow from Week 13 to Week 35 (up to 24 weeks).

Reporting group title	Adalimumab EW/Adalimumab EW (Period 2)
-----------------------	--

Reporting group description:

Subjects randomized to receive adalimumab every week (ew) in Period 1 were re-randomized to receive 40 mg adalimumab ew from Week 12 to Week 35 in Period 2 (up to 24 weeks).

Serious adverse events	Placebo (Period 1)	Adalimumab EW (Period 1)	Placebo/Adalimumab EW (Period 2)
Total subjects affected by serious adverse events			
subjects affected / exposed	5 / 152 (3.29%)	3 / 153 (1.96%)	5 / 145 (3.45%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Invasive ductal breast carcinoma			

subjects affected / exposed	1 / 152 (0.66%)	0 / 153 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Hepatitis A antibody positive subjects affected / exposed	0 / 152 (0.00%)	0 / 153 (0.00%)	1 / 145 (0.69%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Liver function test abnormal subjects affected / exposed	0 / 152 (0.00%)	0 / 153 (0.00%)	1 / 145 (0.69%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Surgical and medical procedures			
Abortion induced subjects affected / exposed	0 / 152 (0.00%)	0 / 153 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pregnancy, puerperium and perinatal conditions			
Ectopic pregnancy subjects affected / exposed	0 / 152 (0.00%)	0 / 153 (0.00%)	1 / 145 (0.69%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Effusion subjects affected / exposed	1 / 152 (0.66%)	0 / 153 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain subjects affected / exposed	0 / 152 (0.00%)	0 / 153 (0.00%)	1 / 145 (0.69%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			

Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 152 (0.00%)	1 / 153 (0.65%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Hidradenitis			
subjects affected / exposed	3 / 152 (1.97%)	1 / 153 (0.65%)	2 / 145 (1.38%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Intervertebral disc calcification			
subjects affected / exposed	1 / 152 (0.66%)	0 / 153 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tendonitis			
subjects affected / exposed	1 / 152 (0.66%)	0 / 153 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Pyelonephritis			
subjects affected / exposed	0 / 152 (0.00%)	1 / 153 (0.65%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 152 (0.00%)	0 / 153 (0.00%)	1 / 145 (0.69%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Adalimumab EW/Placebo (Period 2)	Adalimumab EW/Adalimumab EOW (Period 2)	Adalimumab EW/Adalimumab EW (Period 2)
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 49 (4.08%)	3 / 48 (6.25%)	1 / 48 (2.08%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			

Neoplasms benign, malignant and unspecified (incl cysts and polyps) Invasive ductal breast carcinoma subjects affected / exposed	0 / 49 (0.00%)	0 / 48 (0.00%)	0 / 48 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations Hepatitis A antibody positive subjects affected / exposed	0 / 49 (0.00%)	0 / 48 (0.00%)	0 / 48 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Liver function test abnormal subjects affected / exposed	0 / 49 (0.00%)	0 / 48 (0.00%)	0 / 48 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Surgical and medical procedures Abortion induced subjects affected / exposed	0 / 49 (0.00%)	1 / 48 (2.08%)	0 / 48 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pregnancy, puerperium and perinatal conditions Ectopic pregnancy subjects affected / exposed	0 / 49 (0.00%)	0 / 48 (0.00%)	1 / 48 (2.08%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions Effusion subjects affected / exposed	0 / 49 (0.00%)	0 / 48 (0.00%)	0 / 48 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders Abdominal pain subjects affected / exposed	0 / 49 (0.00%)	0 / 48 (0.00%)	0 / 48 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Respiratory, thoracic and mediastinal disorders			
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 49 (0.00%)	0 / 48 (0.00%)	0 / 48 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Hidradenitis			
subjects affected / exposed	2 / 49 (4.08%)	2 / 48 (4.17%)	0 / 48 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Intervertebral disc calcification			
subjects affected / exposed	0 / 49 (0.00%)	0 / 48 (0.00%)	0 / 48 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tendonitis			
subjects affected / exposed	0 / 49 (0.00%)	0 / 48 (0.00%)	0 / 48 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Pyelonephritis			
subjects affected / exposed	0 / 49 (0.00%)	0 / 48 (0.00%)	0 / 48 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 49 (0.00%)	0 / 48 (0.00%)	0 / 48 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 2 %

Non-serious adverse events	Placebo (Period 1)	Adalimumab EW (Period 1)	Placebo/Adalimumab EW (Period 2)
Total subjects affected by non-serious adverse events subjects affected / exposed	81 / 152 (53.29%)	64 / 153 (41.83%)	68 / 145 (46.90%)
Vascular disorders			
Hypertension subjects affected / exposed	3 / 152 (1.97%)	1 / 153 (0.65%)	2 / 145 (1.38%)
occurrences (all)	3	1	2
General disorders and administration site conditions			
Fatigue subjects affected / exposed	4 / 152 (2.63%)	3 / 153 (1.96%)	2 / 145 (1.38%)
occurrences (all)	6	3	2
Pyrexia subjects affected / exposed	3 / 152 (1.97%)	1 / 153 (0.65%)	2 / 145 (1.38%)
occurrences (all)	4	1	2
Chills subjects affected / exposed	1 / 152 (0.66%)	0 / 153 (0.00%)	0 / 145 (0.00%)
occurrences (all)	1	0	0
Injection site bruising subjects affected / exposed	0 / 152 (0.00%)	1 / 153 (0.65%)	1 / 145 (0.69%)
occurrences (all)	0	2	1
Injection site erythema subjects affected / exposed	0 / 152 (0.00%)	1 / 153 (0.65%)	6 / 145 (4.14%)
occurrences (all)	0	1	16
Injection site pruritus subjects affected / exposed	0 / 152 (0.00%)	1 / 153 (0.65%)	3 / 145 (2.07%)
occurrences (all)	0	1	13
Local swelling subjects affected / exposed	0 / 152 (0.00%)	0 / 153 (0.00%)	0 / 145 (0.00%)
occurrences (all)	0	0	0
Non-cardiac chest pain subjects affected / exposed	0 / 152 (0.00%)	0 / 153 (0.00%)	0 / 145 (0.00%)
occurrences (all)	0	0	0
Xerosis subjects affected / exposed	0 / 152 (0.00%)	0 / 153 (0.00%)	0 / 145 (0.00%)
occurrences (all)	0	0	0
Immune system disorders			

Hypersensitivity subjects affected / exposed occurrences (all)	0 / 152 (0.00%) 0	0 / 153 (0.00%) 0	0 / 145 (0.00%) 0
Reproductive system and breast disorders Vaginal haemorrhage subjects affected / exposed occurrences (all)	0 / 152 (0.00%) 0	0 / 153 (0.00%) 0	0 / 145 (0.00%) 0
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain subjects affected / exposed occurrences (all)	4 / 152 (2.63%) 4	2 / 153 (1.31%) 3	3 / 145 (2.07%) 3
Asthma subjects affected / exposed occurrences (all)	0 / 152 (0.00%) 0	0 / 153 (0.00%) 0	0 / 145 (0.00%) 0
Cough subjects affected / exposed occurrences (all)	3 / 152 (1.97%) 3	2 / 153 (1.31%) 2	2 / 145 (1.38%) 3
Respiratory tract congestion subjects affected / exposed occurrences (all)	0 / 152 (0.00%) 0	1 / 153 (0.65%) 1	1 / 145 (0.69%) 1
Sinus congestion subjects affected / exposed occurrences (all)	1 / 152 (0.66%) 1	1 / 153 (0.65%) 1	1 / 145 (0.69%) 1
Sneezing subjects affected / exposed occurrences (all)	0 / 152 (0.00%) 0	0 / 153 (0.00%) 0	0 / 145 (0.00%) 0
Psychiatric disorders Depression subjects affected / exposed occurrences (all)	0 / 152 (0.00%) 0	3 / 153 (1.96%) 3	2 / 145 (1.38%) 2
Insomnia subjects affected / exposed occurrences (all)	1 / 152 (0.66%) 1	1 / 153 (0.65%) 1	1 / 145 (0.69%) 1
Investigations Alanine aminotransferase increased			

subjects affected / exposed occurrences (all)	0 / 152 (0.00%) 0	0 / 153 (0.00%) 0	2 / 145 (1.38%) 2
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	0 / 152 (0.00%) 0	1 / 153 (0.65%) 1	2 / 145 (1.38%) 2
Blood glucose increased subjects affected / exposed occurrences (all)	0 / 152 (0.00%) 0	0 / 153 (0.00%) 0	1 / 145 (0.69%) 1
Blood triglycerides increased subjects affected / exposed occurrences (all)	1 / 152 (0.66%) 1	0 / 153 (0.00%) 0	0 / 145 (0.00%) 0
C-reactive protein increased subjects affected / exposed occurrences (all)	3 / 152 (1.97%) 3	3 / 153 (1.96%) 3	2 / 145 (1.38%) 2
Weight decreased subjects affected / exposed occurrences (all)	0 / 152 (0.00%) 0	2 / 153 (1.31%) 2	0 / 145 (0.00%) 0
Weight increased subjects affected / exposed occurrences (all)	3 / 152 (1.97%) 3	3 / 153 (1.96%) 3	2 / 145 (1.38%) 2
White blood cell count decreased subjects affected / exposed occurrences (all)	0 / 152 (0.00%) 0	0 / 153 (0.00%) 0	0 / 145 (0.00%) 0
Blood alkaline phosphatase increased subjects affected / exposed occurrences (all)	0 / 152 (0.00%) 0	0 / 153 (0.00%) 0	0 / 145 (0.00%) 0
Injury, poisoning and procedural complications			
Contusion subjects affected / exposed occurrences (all)	2 / 152 (1.32%) 2	0 / 153 (0.00%) 0	2 / 145 (1.38%) 2
Excoriation subjects affected / exposed occurrences (all)	0 / 152 (0.00%) 0	0 / 153 (0.00%) 0	0 / 145 (0.00%) 0
Fall			

subjects affected / exposed occurrences (all)	1 / 152 (0.66%) 1	0 / 153 (0.00%) 0	0 / 145 (0.00%) 0
Ligament sprain subjects affected / exposed occurrences (all)	1 / 152 (0.66%) 1	1 / 153 (0.65%) 1	1 / 145 (0.69%) 1
Road traffic accident subjects affected / exposed occurrences (all)	0 / 152 (0.00%) 0	1 / 153 (0.65%) 1	0 / 145 (0.00%) 0
Skin injury subjects affected / exposed occurrences (all)	0 / 152 (0.00%) 0	0 / 153 (0.00%) 0	0 / 145 (0.00%) 0
Nervous system disorders			
Headache subjects affected / exposed occurrences (all)	15 / 152 (9.87%) 18	14 / 153 (9.15%) 19	9 / 145 (6.21%) 14
Dizziness subjects affected / exposed occurrences (all)	2 / 152 (1.32%) 2	4 / 153 (2.61%) 4	1 / 145 (0.69%) 1
Lethargy subjects affected / exposed occurrences (all)	0 / 152 (0.00%) 0	1 / 153 (0.65%) 1	0 / 145 (0.00%) 0
Nerve compression subjects affected / exposed occurrences (all)	0 / 152 (0.00%) 0	0 / 153 (0.00%) 0	0 / 145 (0.00%) 0
Paraesthesia subjects affected / exposed occurrences (all)	1 / 152 (0.66%) 1	0 / 153 (0.00%) 0	1 / 145 (0.69%) 1
Sinus headache subjects affected / exposed occurrences (all)	1 / 152 (0.66%) 1	0 / 153 (0.00%) 0	0 / 145 (0.00%) 0
Syncope subjects affected / exposed occurrences (all)	0 / 152 (0.00%) 0	0 / 153 (0.00%) 0	0 / 145 (0.00%) 0
Blood and lymphatic system disorders Anaemia			

subjects affected / exposed occurrences (all)	1 / 152 (0.66%) 1	1 / 153 (0.65%) 1	1 / 145 (0.69%) 1
Leukocytosis subjects affected / exposed occurrences (all)	0 / 152 (0.00%) 0	0 / 153 (0.00%) 0	2 / 145 (1.38%) 2
Neutrophilia subjects affected / exposed occurrences (all)	1 / 152 (0.66%) 1	0 / 153 (0.00%) 0	1 / 145 (0.69%) 1
Ear and labyrinth disorders Vertigo subjects affected / exposed occurrences (all)	0 / 152 (0.00%) 0	0 / 153 (0.00%) 0	0 / 145 (0.00%) 0
Eye disorders Blepharitis subjects affected / exposed occurrences (all)	0 / 152 (0.00%) 0	0 / 153 (0.00%) 0	0 / 145 (0.00%) 0
Eyelid oedema subjects affected / exposed occurrences (all)	0 / 152 (0.00%) 0	0 / 153 (0.00%) 0	0 / 145 (0.00%) 0
Meibomian gland dysfunction subjects affected / exposed occurrences (all)	0 / 152 (0.00%) 0	0 / 153 (0.00%) 0	0 / 145 (0.00%) 0
Visual impairment subjects affected / exposed occurrences (all)	0 / 152 (0.00%) 0	0 / 153 (0.00%) 0	0 / 145 (0.00%) 0
Gastrointestinal disorders Nausea subjects affected / exposed occurrences (all)	4 / 152 (2.63%) 4	3 / 153 (1.96%) 3	6 / 145 (4.14%) 6
Abdominal pain upper subjects affected / exposed occurrences (all)	3 / 152 (1.97%) 3	1 / 153 (0.65%) 1	1 / 145 (0.69%) 2
Constipation subjects affected / exposed occurrences (all)	2 / 152 (1.32%) 2	1 / 153 (0.65%) 1	1 / 145 (0.69%) 1
Diarrhoea			

subjects affected / exposed occurrences (all)	2 / 152 (1.32%) 2	3 / 153 (1.96%) 3	3 / 145 (2.07%) 3
Dry mouth subjects affected / exposed occurrences (all)	0 / 152 (0.00%) 0	0 / 153 (0.00%) 0	0 / 145 (0.00%) 0
Gastritis subjects affected / exposed occurrences (all)	0 / 152 (0.00%) 0	0 / 153 (0.00%) 0	0 / 145 (0.00%) 0
Lip swelling subjects affected / exposed occurrences (all)	0 / 152 (0.00%) 0	0 / 153 (0.00%) 0	0 / 145 (0.00%) 0
Toothache subjects affected / exposed occurrences (all)	1 / 152 (0.66%) 1	0 / 153 (0.00%) 0	2 / 145 (1.38%) 2
Vomiting subjects affected / exposed occurrences (all)	2 / 152 (1.32%) 2	1 / 153 (0.65%) 1	1 / 145 (0.69%) 1
Hepatobiliary disorders Cholelithiasis subjects affected / exposed occurrences (all)	0 / 152 (0.00%) 0	0 / 153 (0.00%) 0	0 / 145 (0.00%) 0
Skin and subcutaneous tissue disorders Dermatitis contact subjects affected / exposed occurrences (all)	1 / 152 (0.66%) 1	0 / 153 (0.00%) 0	1 / 145 (0.69%) 2
Hidradenitis subjects affected / exposed occurrences (all)	17 / 152 (11.18%) 23	13 / 153 (8.50%) 15	14 / 145 (9.66%) 14
Acne cystic subjects affected / exposed occurrences (all)	0 / 152 (0.00%) 0	0 / 153 (0.00%) 0	0 / 145 (0.00%) 0
Alopecia subjects affected / exposed occurrences (all)	0 / 152 (0.00%) 0	0 / 153 (0.00%) 0	0 / 145 (0.00%) 0
Dermal cyst			

subjects affected / exposed occurrences (all)	2 / 152 (1.32%) 2	0 / 153 (0.00%) 0	2 / 145 (1.38%) 2
Dermatitis papillaris capillitii subjects affected / exposed occurrences (all)	0 / 152 (0.00%) 0	0 / 153 (0.00%) 0	0 / 145 (0.00%) 0
Dermatitis psoriasiform subjects affected / exposed occurrences (all)	0 / 152 (0.00%) 0	0 / 153 (0.00%) 0	1 / 145 (0.69%) 1
Eczema subjects affected / exposed occurrences (all)	0 / 152 (0.00%) 0	1 / 153 (0.65%) 1	1 / 145 (0.69%) 1
Eczema asteatotic subjects affected / exposed occurrences (all)	0 / 152 (0.00%) 0	0 / 153 (0.00%) 0	0 / 145 (0.00%) 0
Intertrigo subjects affected / exposed occurrences (all)	2 / 152 (1.32%) 2	1 / 153 (0.65%) 1	1 / 145 (0.69%) 1
Keloid scar subjects affected / exposed occurrences (all)	0 / 152 (0.00%) 0	0 / 153 (0.00%) 0	0 / 145 (0.00%) 0
Renal and urinary disorders			
Dysuria subjects affected / exposed occurrences (all)	0 / 152 (0.00%) 0	0 / 153 (0.00%) 0	0 / 145 (0.00%) 0
Haematuria subjects affected / exposed occurrences (all)	0 / 152 (0.00%) 0	0 / 153 (0.00%) 0	0 / 145 (0.00%) 0
Endocrine disorders			
Hypothyroidism subjects affected / exposed occurrences (all)	0 / 152 (0.00%) 0	0 / 153 (0.00%) 0	1 / 145 (0.69%) 1
Musculoskeletal and connective tissue disorders			
Arthralgia subjects affected / exposed occurrences (all)	0 / 152 (0.00%) 0	3 / 153 (1.96%) 3	1 / 145 (0.69%) 1
Back pain			

subjects affected / exposed	4 / 152 (2.63%)	3 / 153 (1.96%)	1 / 145 (0.69%)
occurrences (all)	4	3	1
Intervertebral disc degeneration			
subjects affected / exposed	0 / 152 (0.00%)	0 / 153 (0.00%)	1 / 145 (0.69%)
occurrences (all)	0	0	1
Joint swelling			
subjects affected / exposed	0 / 152 (0.00%)	0 / 153 (0.00%)	0 / 145 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal stiffness			
subjects affected / exposed	1 / 152 (0.66%)	0 / 153 (0.00%)	0 / 145 (0.00%)
occurrences (all)	1	0	0
Myalgia			
subjects affected / exposed	1 / 152 (0.66%)	2 / 153 (1.31%)	3 / 145 (2.07%)
occurrences (all)	1	2	3
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	16 / 152 (10.53%)	9 / 153 (5.88%)	11 / 145 (7.59%)
occurrences (all)	16	9	12
Upper respiratory tract infection			
subjects affected / exposed	4 / 152 (2.63%)	5 / 153 (3.27%)	5 / 145 (3.45%)
occurrences (all)	4	5	6
Urinary tract infection			
subjects affected / exposed	3 / 152 (1.97%)	5 / 153 (3.27%)	4 / 145 (2.76%)
occurrences (all)	3	5	4
Body tinea			
subjects affected / exposed	0 / 152 (0.00%)	0 / 153 (0.00%)	0 / 145 (0.00%)
occurrences (all)	0	0	0
Bronchitis			
subjects affected / exposed	2 / 152 (1.32%)	0 / 153 (0.00%)	3 / 145 (2.07%)
occurrences (all)	2	0	3
Cellulitis			
subjects affected / exposed	2 / 152 (1.32%)	2 / 153 (1.31%)	0 / 145 (0.00%)
occurrences (all)	2	2	0
Cytolytic vaginosis			
subjects affected / exposed	0 / 152 (0.00%)	0 / 153 (0.00%)	0 / 145 (0.00%)
occurrences (all)	0	0	0

Ear infection			
subjects affected / exposed	0 / 152 (0.00%)	1 / 153 (0.65%)	0 / 145 (0.00%)
occurrences (all)	0	1	0
Folliculitis			
subjects affected / exposed	1 / 152 (0.66%)	0 / 153 (0.00%)	2 / 145 (1.38%)
occurrences (all)	1	0	2
Impetigo			
subjects affected / exposed	0 / 152 (0.00%)	0 / 153 (0.00%)	0 / 145 (0.00%)
occurrences (all)	0	0	0
Influenza			
subjects affected / exposed	3 / 152 (1.97%)	2 / 153 (1.31%)	3 / 145 (2.07%)
occurrences (all)	3	2	4
Lower respiratory tract infection			
subjects affected / exposed	2 / 152 (1.32%)	0 / 153 (0.00%)	0 / 145 (0.00%)
occurrences (all)	2	0	0
Measles			
subjects affected / exposed	0 / 152 (0.00%)	0 / 153 (0.00%)	0 / 145 (0.00%)
occurrences (all)	0	0	0
Oral herpes			
subjects affected / exposed	1 / 152 (0.66%)	0 / 153 (0.00%)	1 / 145 (0.69%)
occurrences (all)	1	0	1
Otitis media			
subjects affected / exposed	0 / 152 (0.00%)	1 / 153 (0.65%)	0 / 145 (0.00%)
occurrences (all)	0	1	0
Pharyngitis			
subjects affected / exposed	0 / 152 (0.00%)	0 / 153 (0.00%)	1 / 145 (0.69%)
occurrences (all)	0	0	1
Pharyngitis streptococcal			
subjects affected / exposed	1 / 152 (0.66%)	1 / 153 (0.65%)	2 / 145 (1.38%)
occurrences (all)	1	1	2
Pneumonia			
subjects affected / exposed	1 / 152 (0.66%)	0 / 153 (0.00%)	1 / 145 (0.69%)
occurrences (all)	1	0	1
Postoperative wound infection			
subjects affected / exposed	0 / 152 (0.00%)	0 / 153 (0.00%)	0 / 145 (0.00%)
occurrences (all)	0	0	0

Rash pustular			
subjects affected / exposed	0 / 152 (0.00%)	0 / 153 (0.00%)	0 / 145 (0.00%)
occurrences (all)	0	0	0
Rhinitis			
subjects affected / exposed	1 / 152 (0.66%)	1 / 153 (0.65%)	0 / 145 (0.00%)
occurrences (all)	1	1	0
Sinusitis			
subjects affected / exposed	1 / 152 (0.66%)	3 / 153 (1.96%)	4 / 145 (2.76%)
occurrences (all)	1	3	4
Skin candida			
subjects affected / exposed	1 / 152 (0.66%)	0 / 153 (0.00%)	1 / 145 (0.69%)
occurrences (all)	1	0	1
Tinea infection			
subjects affected / exposed	0 / 152 (0.00%)	0 / 153 (0.00%)	0 / 145 (0.00%)
occurrences (all)	0	0	0
Tonsillitis			
subjects affected / exposed	1 / 152 (0.66%)	1 / 153 (0.65%)	2 / 145 (1.38%)
occurrences (all)	1	1	2
Tracheitis			
subjects affected / exposed	0 / 152 (0.00%)	0 / 153 (0.00%)	0 / 145 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			
Diabetes mellitus			
subjects affected / exposed	1 / 152 (0.66%)	0 / 153 (0.00%)	0 / 145 (0.00%)
occurrences (all)	1	0	0
Hyperglycaemia			
subjects affected / exposed	0 / 152 (0.00%)	0 / 153 (0.00%)	1 / 145 (0.69%)
occurrences (all)	0	0	1
Hyperlipidaemia			
subjects affected / exposed	0 / 152 (0.00%)	0 / 153 (0.00%)	0 / 145 (0.00%)
occurrences (all)	0	0	0
Hypokalaemia			
subjects affected / exposed	0 / 152 (0.00%)	0 / 153 (0.00%)	1 / 145 (0.69%)
occurrences (all)	0	0	1
Type 2 diabetes mellitus			

subjects affected / exposed occurrences (all)	1 / 152 (0.66%) 1	0 / 153 (0.00%) 0	0 / 145 (0.00%) 0
Vitamin D deficiency subjects affected / exposed occurrences (all)	0 / 152 (0.00%) 0	0 / 153 (0.00%) 0	1 / 145 (0.69%) 1

Non-serious adverse events	Adalimumab EW/Placebo (Period 2)	Adalimumab EW/ Adalimumab EOW (Period 2)	Adalimumab EW/Adalimumab EW (Period 2)
Total subjects affected by non-serious adverse events subjects affected / exposed	30 / 49 (61.22%)	24 / 48 (50.00%)	28 / 48 (58.33%)
Vascular disorders Hypertension subjects affected / exposed occurrences (all)	2 / 49 (4.08%) 2	0 / 48 (0.00%) 0	1 / 48 (2.08%) 1
General disorders and administration site conditions Fatigue subjects affected / exposed occurrences (all)	0 / 49 (0.00%) 0	0 / 48 (0.00%) 0	0 / 48 (0.00%) 0
Pyrexia subjects affected / exposed occurrences (all)	0 / 49 (0.00%) 0	3 / 48 (6.25%) 3	2 / 48 (4.17%) 2
Chills subjects affected / exposed occurrences (all)	0 / 49 (0.00%) 0	0 / 48 (0.00%) 0	1 / 48 (2.08%) 1
Injection site bruising subjects affected / exposed occurrences (all)	1 / 49 (2.04%) 1	0 / 48 (0.00%) 0	0 / 48 (0.00%) 0
Injection site erythema subjects affected / exposed occurrences (all)	0 / 49 (0.00%) 0	0 / 48 (0.00%) 0	0 / 48 (0.00%) 0
Injection site pruritus subjects affected / exposed occurrences (all)	0 / 49 (0.00%) 0	0 / 48 (0.00%) 0	1 / 48 (2.08%) 1
Local swelling subjects affected / exposed occurrences (all)	0 / 49 (0.00%) 0	0 / 48 (0.00%) 0	1 / 48 (2.08%) 1
Non-cardiac chest pain			

subjects affected / exposed occurrences (all)	0 / 49 (0.00%) 0	0 / 48 (0.00%) 0	1 / 48 (2.08%) 1
Xerosis subjects affected / exposed occurrences (all)	0 / 49 (0.00%) 0	0 / 48 (0.00%) 0	1 / 48 (2.08%) 1
Immune system disorders Hypersensitivity subjects affected / exposed occurrences (all)	0 / 49 (0.00%) 0	1 / 48 (2.08%) 1	0 / 48 (0.00%) 0
Reproductive system and breast disorders Vaginal haemorrhage subjects affected / exposed occurrences (all)	0 / 49 (0.00%) 0	1 / 48 (2.08%) 1	0 / 48 (0.00%) 0
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain subjects affected / exposed occurrences (all)	1 / 49 (2.04%) 1	0 / 48 (0.00%) 0	0 / 48 (0.00%) 0
Asthma subjects affected / exposed occurrences (all)	1 / 49 (2.04%) 1	0 / 48 (0.00%) 0	0 / 48 (0.00%) 0
Cough subjects affected / exposed occurrences (all)	0 / 49 (0.00%) 0	1 / 48 (2.08%) 1	2 / 48 (4.17%) 2
Respiratory tract congestion subjects affected / exposed occurrences (all)	0 / 49 (0.00%) 0	0 / 48 (0.00%) 0	1 / 48 (2.08%) 1
Sinus congestion subjects affected / exposed occurrences (all)	0 / 49 (0.00%) 0	0 / 48 (0.00%) 0	1 / 48 (2.08%) 1
Sneezing subjects affected / exposed occurrences (all)	0 / 49 (0.00%) 0	1 / 48 (2.08%) 1	0 / 48 (0.00%) 0
Psychiatric disorders Depression subjects affected / exposed occurrences (all)	1 / 49 (2.04%) 1	0 / 48 (0.00%) 0	0 / 48 (0.00%) 0

Insomnia subjects affected / exposed occurrences (all)	0 / 49 (0.00%) 0	1 / 48 (2.08%) 1	2 / 48 (4.17%) 2
Investigations			
Alanine aminotransferase increased subjects affected / exposed occurrences (all)	2 / 49 (4.08%) 2	0 / 48 (0.00%) 0	0 / 48 (0.00%) 0
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	1 / 49 (2.04%) 1	0 / 48 (0.00%) 0	0 / 48 (0.00%) 0
Blood glucose increased subjects affected / exposed occurrences (all)	0 / 49 (0.00%) 0	1 / 48 (2.08%) 1	0 / 48 (0.00%) 0
Blood triglycerides increased subjects affected / exposed occurrences (all)	1 / 49 (2.04%) 1	0 / 48 (0.00%) 0	0 / 48 (0.00%) 0
C-reactive protein increased subjects affected / exposed occurrences (all)	1 / 49 (2.04%) 1	0 / 48 (0.00%) 0	0 / 48 (0.00%) 0
Weight decreased subjects affected / exposed occurrences (all)	0 / 49 (0.00%) 0	0 / 48 (0.00%) 0	2 / 48 (4.17%) 2
Weight increased subjects affected / exposed occurrences (all)	0 / 49 (0.00%) 0	0 / 48 (0.00%) 0	1 / 48 (2.08%) 1
White blood cell count decreased subjects affected / exposed occurrences (all)	1 / 49 (2.04%) 1	0 / 48 (0.00%) 0	0 / 48 (0.00%) 0
Blood alkaline phosphatase increased subjects affected / exposed occurrences (all)	1 / 49 (2.04%) 1	0 / 48 (0.00%) 0	0 / 48 (0.00%) 0
Injury, poisoning and procedural complications			
Contusion subjects affected / exposed occurrences (all)	1 / 49 (2.04%) 1	0 / 48 (0.00%) 0	0 / 48 (0.00%) 0
Excoriation			

subjects affected / exposed	1 / 49 (2.04%)	0 / 48 (0.00%)	0 / 48 (0.00%)
occurrences (all)	1	0	0
Fall			
subjects affected / exposed	1 / 49 (2.04%)	0 / 48 (0.00%)	0 / 48 (0.00%)
occurrences (all)	1	0	0
Ligament sprain			
subjects affected / exposed	0 / 49 (0.00%)	0 / 48 (0.00%)	1 / 48 (2.08%)
occurrences (all)	0	0	1
Road traffic accident			
subjects affected / exposed	1 / 49 (2.04%)	0 / 48 (0.00%)	0 / 48 (0.00%)
occurrences (all)	1	0	0
Skin injury			
subjects affected / exposed	0 / 49 (0.00%)	1 / 48 (2.08%)	0 / 48 (0.00%)
occurrences (all)	0	1	0
Nervous system disorders			
Headache			
subjects affected / exposed	4 / 49 (8.16%)	3 / 48 (6.25%)	2 / 48 (4.17%)
occurrences (all)	9	3	7
Dizziness			
subjects affected / exposed	1 / 49 (2.04%)	2 / 48 (4.17%)	0 / 48 (0.00%)
occurrences (all)	1	2	0
Lethargy			
subjects affected / exposed	0 / 49 (0.00%)	0 / 48 (0.00%)	1 / 48 (2.08%)
occurrences (all)	0	0	1
Nerve compression			
subjects affected / exposed	1 / 49 (2.04%)	0 / 48 (0.00%)	0 / 48 (0.00%)
occurrences (all)	1	0	0
Paraesthesia			
subjects affected / exposed	1 / 49 (2.04%)	0 / 48 (0.00%)	0 / 48 (0.00%)
occurrences (all)	1	0	0
Sinus headache			
subjects affected / exposed	0 / 49 (0.00%)	0 / 48 (0.00%)	1 / 48 (2.08%)
occurrences (all)	0	0	1
Syncope			
subjects affected / exposed	0 / 49 (0.00%)	0 / 48 (0.00%)	1 / 48 (2.08%)
occurrences (all)	0	0	1

Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 49 (2.04%)	0 / 48 (0.00%)	2 / 48 (4.17%)
occurrences (all)	1	0	2
Leukocytosis			
subjects affected / exposed	1 / 49 (2.04%)	0 / 48 (0.00%)	0 / 48 (0.00%)
occurrences (all)	1	0	0
Neutrophilia			
subjects affected / exposed	1 / 49 (2.04%)	0 / 48 (0.00%)	0 / 48 (0.00%)
occurrences (all)	1	0	0
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	0 / 49 (0.00%)	0 / 48 (0.00%)	1 / 48 (2.08%)
occurrences (all)	0	0	1
Eye disorders			
Blepharitis			
subjects affected / exposed	0 / 49 (0.00%)	0 / 48 (0.00%)	1 / 48 (2.08%)
occurrences (all)	0	0	1
Eyelid oedema			
subjects affected / exposed	1 / 49 (2.04%)	0 / 48 (0.00%)	0 / 48 (0.00%)
occurrences (all)	1	0	0
Meibomian gland dysfunction			
subjects affected / exposed	0 / 49 (0.00%)	0 / 48 (0.00%)	1 / 48 (2.08%)
occurrences (all)	0	0	1
Visual impairment			
subjects affected / exposed	1 / 49 (2.04%)	0 / 48 (0.00%)	0 / 48 (0.00%)
occurrences (all)	1	0	0
Gastrointestinal disorders			
Nausea			
subjects affected / exposed	0 / 49 (0.00%)	0 / 48 (0.00%)	2 / 48 (4.17%)
occurrences (all)	0	0	2
Abdominal pain upper			
subjects affected / exposed	2 / 49 (4.08%)	0 / 48 (0.00%)	0 / 48 (0.00%)
occurrences (all)	2	0	0
Constipation			
subjects affected / exposed	0 / 49 (0.00%)	0 / 48 (0.00%)	1 / 48 (2.08%)
occurrences (all)	0	0	1

Diarrhoea			
subjects affected / exposed	1 / 49 (2.04%)	0 / 48 (0.00%)	1 / 48 (2.08%)
occurrences (all)	1	0	1
Dry mouth			
subjects affected / exposed	0 / 49 (0.00%)	1 / 48 (2.08%)	0 / 48 (0.00%)
occurrences (all)	0	1	0
Gastritis			
subjects affected / exposed	0 / 49 (0.00%)	0 / 48 (0.00%)	2 / 48 (4.17%)
occurrences (all)	0	0	2
Lip swelling			
subjects affected / exposed	0 / 49 (0.00%)	1 / 48 (2.08%)	0 / 48 (0.00%)
occurrences (all)	0	1	0
Toothache			
subjects affected / exposed	1 / 49 (2.04%)	0 / 48 (0.00%)	0 / 48 (0.00%)
occurrences (all)	1	0	0
Vomiting			
subjects affected / exposed	1 / 49 (2.04%)	1 / 48 (2.08%)	1 / 48 (2.08%)
occurrences (all)	1	1	1
Hepatobiliary disorders			
Cholelithiasis			
subjects affected / exposed	1 / 49 (2.04%)	0 / 48 (0.00%)	0 / 48 (0.00%)
occurrences (all)	1	0	0
Skin and subcutaneous tissue disorders			
Dermatitis contact			
subjects affected / exposed	0 / 49 (0.00%)	3 / 48 (6.25%)	0 / 48 (0.00%)
occurrences (all)	0	3	0
Hidradenitis			
subjects affected / exposed	8 / 49 (16.33%)	7 / 48 (14.58%)	2 / 48 (4.17%)
occurrences (all)	8	7	2
Acne cystic			
subjects affected / exposed	0 / 49 (0.00%)	0 / 48 (0.00%)	1 / 48 (2.08%)
occurrences (all)	0	0	1
Alopecia			
subjects affected / exposed	0 / 49 (0.00%)	0 / 48 (0.00%)	1 / 48 (2.08%)
occurrences (all)	0	0	1
Dermal cyst			

subjects affected / exposed	1 / 49 (2.04%)	0 / 48 (0.00%)	0 / 48 (0.00%)
occurrences (all)	1	0	0
Dermatitis papillaris capillitii			
subjects affected / exposed	1 / 49 (2.04%)	0 / 48 (0.00%)	0 / 48 (0.00%)
occurrences (all)	1	0	0
Dermatitis psoriasiform			
subjects affected / exposed	1 / 49 (2.04%)	0 / 48 (0.00%)	1 / 48 (2.08%)
occurrences (all)	1	0	1
Eczema			
subjects affected / exposed	1 / 49 (2.04%)	0 / 48 (0.00%)	0 / 48 (0.00%)
occurrences (all)	1	0	0
Eczema asteatotic			
subjects affected / exposed	1 / 49 (2.04%)	0 / 48 (0.00%)	0 / 48 (0.00%)
occurrences (all)	1	0	0
Intertrigo			
subjects affected / exposed	1 / 49 (2.04%)	0 / 48 (0.00%)	2 / 48 (4.17%)
occurrences (all)	2	0	2
Keloid scar			
subjects affected / exposed	0 / 49 (0.00%)	1 / 48 (2.08%)	0 / 48 (0.00%)
occurrences (all)	0	1	0
Renal and urinary disorders			
Dysuria			
subjects affected / exposed	0 / 49 (0.00%)	0 / 48 (0.00%)	1 / 48 (2.08%)
occurrences (all)	0	0	1
Haematuria			
subjects affected / exposed	1 / 49 (2.04%)	0 / 48 (0.00%)	0 / 48 (0.00%)
occurrences (all)	1	0	0
Endocrine disorders			
Hypothyroidism			
subjects affected / exposed	0 / 49 (0.00%)	1 / 48 (2.08%)	0 / 48 (0.00%)
occurrences (all)	0	1	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	3 / 49 (6.12%)	1 / 48 (2.08%)	1 / 48 (2.08%)
occurrences (all)	3	1	1
Back pain			

subjects affected / exposed	1 / 49 (2.04%)	0 / 48 (0.00%)	1 / 48 (2.08%)
occurrences (all)	1	0	1
Intervertebral disc degeneration			
subjects affected / exposed	0 / 49 (0.00%)	0 / 48 (0.00%)	1 / 48 (2.08%)
occurrences (all)	0	0	1
Joint swelling			
subjects affected / exposed	1 / 49 (2.04%)	0 / 48 (0.00%)	0 / 48 (0.00%)
occurrences (all)	1	0	0
Musculoskeletal stiffness			
subjects affected / exposed	0 / 49 (0.00%)	0 / 48 (0.00%)	1 / 48 (2.08%)
occurrences (all)	0	0	1
Myalgia			
subjects affected / exposed	1 / 49 (2.04%)	0 / 48 (0.00%)	0 / 48 (0.00%)
occurrences (all)	1	0	0
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	9 / 49 (18.37%)	1 / 48 (2.08%)	3 / 48 (6.25%)
occurrences (all)	15	2	3
Upper respiratory tract infection			
subjects affected / exposed	2 / 49 (4.08%)	3 / 48 (6.25%)	4 / 48 (8.33%)
occurrences (all)	2	4	4
Urinary tract infection			
subjects affected / exposed	1 / 49 (2.04%)	2 / 48 (4.17%)	2 / 48 (4.17%)
occurrences (all)	1	3	3
Body tinea			
subjects affected / exposed	0 / 49 (0.00%)	0 / 48 (0.00%)	1 / 48 (2.08%)
occurrences (all)	0	0	1
Bronchitis			
subjects affected / exposed	0 / 49 (0.00%)	1 / 48 (2.08%)	0 / 48 (0.00%)
occurrences (all)	0	1	0
Cellulitis			
subjects affected / exposed	1 / 49 (2.04%)	0 / 48 (0.00%)	0 / 48 (0.00%)
occurrences (all)	1	0	0
Cytolytic vaginosis			
subjects affected / exposed	0 / 49 (0.00%)	0 / 48 (0.00%)	1 / 48 (2.08%)
occurrences (all)	0	0	1

Ear infection			
subjects affected / exposed	0 / 49 (0.00%)	0 / 48 (0.00%)	1 / 48 (2.08%)
occurrences (all)	0	0	1
Folliculitis			
subjects affected / exposed	0 / 49 (0.00%)	1 / 48 (2.08%)	2 / 48 (4.17%)
occurrences (all)	0	2	2
Impetigo			
subjects affected / exposed	0 / 49 (0.00%)	1 / 48 (2.08%)	0 / 48 (0.00%)
occurrences (all)	0	1	0
Influenza			
subjects affected / exposed	0 / 49 (0.00%)	0 / 48 (0.00%)	1 / 48 (2.08%)
occurrences (all)	0	0	1
Lower respiratory tract infection			
subjects affected / exposed	1 / 49 (2.04%)	1 / 48 (2.08%)	0 / 48 (0.00%)
occurrences (all)	1	1	0
Measles			
subjects affected / exposed	0 / 49 (0.00%)	1 / 48 (2.08%)	0 / 48 (0.00%)
occurrences (all)	0	1	0
Oral herpes			
subjects affected / exposed	1 / 49 (2.04%)	0 / 48 (0.00%)	0 / 48 (0.00%)
occurrences (all)	1	0	0
Otitis media			
subjects affected / exposed	0 / 49 (0.00%)	1 / 48 (2.08%)	0 / 48 (0.00%)
occurrences (all)	0	1	0
Pharyngitis			
subjects affected / exposed	0 / 49 (0.00%)	0 / 48 (0.00%)	1 / 48 (2.08%)
occurrences (all)	0	0	1
Pharyngitis streptococcal			
subjects affected / exposed	1 / 49 (2.04%)	0 / 48 (0.00%)	0 / 48 (0.00%)
occurrences (all)	1	0	0
Pneumonia			
subjects affected / exposed	0 / 49 (0.00%)	1 / 48 (2.08%)	0 / 48 (0.00%)
occurrences (all)	0	1	0
Postoperative wound infection			
subjects affected / exposed	1 / 49 (2.04%)	0 / 48 (0.00%)	0 / 48 (0.00%)
occurrences (all)	1	0	0

Rash pustular			
subjects affected / exposed	1 / 49 (2.04%)	0 / 48 (0.00%)	0 / 48 (0.00%)
occurrences (all)	1	0	0
Rhinitis			
subjects affected / exposed	1 / 49 (2.04%)	0 / 48 (0.00%)	0 / 48 (0.00%)
occurrences (all)	1	0	0
Sinusitis			
subjects affected / exposed	1 / 49 (2.04%)	0 / 48 (0.00%)	2 / 48 (4.17%)
occurrences (all)	1	0	2
Skin candida			
subjects affected / exposed	1 / 49 (2.04%)	0 / 48 (0.00%)	0 / 48 (0.00%)
occurrences (all)	1	0	0
Tinea infection			
subjects affected / exposed	0 / 49 (0.00%)	0 / 48 (0.00%)	1 / 48 (2.08%)
occurrences (all)	0	0	1
Tonsillitis			
subjects affected / exposed	1 / 49 (2.04%)	1 / 48 (2.08%)	0 / 48 (0.00%)
occurrences (all)	1	1	0
Tracheitis			
subjects affected / exposed	1 / 49 (2.04%)	0 / 48 (0.00%)	0 / 48 (0.00%)
occurrences (all)	1	0	0
Metabolism and nutrition disorders			
Diabetes mellitus			
subjects affected / exposed	0 / 49 (0.00%)	1 / 48 (2.08%)	0 / 48 (0.00%)
occurrences (all)	0	1	0
Hyperglycaemia			
subjects affected / exposed	0 / 49 (0.00%)	0 / 48 (0.00%)	1 / 48 (2.08%)
occurrences (all)	0	0	1
Hyperlipidaemia			
subjects affected / exposed	0 / 49 (0.00%)	1 / 48 (2.08%)	0 / 48 (0.00%)
occurrences (all)	0	1	0
Hypokalaemia			
subjects affected / exposed	1 / 49 (2.04%)	0 / 48 (0.00%)	0 / 48 (0.00%)
occurrences (all)	1	0	0
Type 2 diabetes mellitus			

subjects affected / exposed	1 / 49 (2.04%)	0 / 48 (0.00%)	0 / 48 (0.00%)
occurrences (all)	1	0	0
Vitamin D deficiency			
subjects affected / exposed	0 / 49 (0.00%)	0 / 48 (0.00%)	1 / 48 (2.08%)
occurrences (all)	0	0	1

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
12 April 2012	Added lesion count assessments at unscheduled visits after Week 12; added waist circumference measurements to assessments; clarified TB testing at screening; revised anti-TB therapy to a minimum of 4 weeks completed prior to starting TNF inhibitors; provided a process of HIV antibody testing where required by country regulatory authorities; added collection of NRS pain and analgesic use using an electronic device; added representative lesion assessments at premature discontinuation visit if the visit occurred prior to Week 12; for the analysis of proportion of subjects achieving at least 30% reduction at least 1 unity reduction from baseline NRS30 - at worst at Week 12, increase baseline requirement from baseline NRS ≥ 1 to ≥ 3 ; classified methods of handling potential confounding effect on pain assessment when medications for HS or pain were used.
07 August 2013	Added safety monitoring language per AbbVie participation in US FDA-requested TNF inhibitor class wide exploration of the rare appearance of malignancy in patients 30 years of age or younger; provided more details to the risks and benefits of participation; added recently approved biologic therapies as prohibited therapies; clarified that antibiotic rescue therapy dosing regimen must remain stable during the study; added change and percent change from baseline in CRP; added blood samples for biologic marker analysis at Week 36 (or premature discontinuation); replaced pregnancy forms and the pregnancy registry with EDC system entry for pregnancy determination.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported